Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.

Abstract

Chronic kidney disease mineral bone disorders (CKD-MBD) encompass laboratory, vascular and bone abnormalities that might portend a poor prognosis in CKD. In spite of a great effort in elucidating the CKD-MBD natural history and pathogenesis, the underlying mechanisms are still largely unknown. However, a deficit in vitamin D is commonly reported as one of the first steps in CKD-MBD, and numerous epidemiological studies have associated serum vitamin D levels with different markers of cardiovascular disease and the risk of death in different populations. We herein summarize current evidence that links vitamin D deficiency to an adverse outcome and the results of the most recent clinical trials that have investigated the impact of paricalcitol supplementation on hard outcome in CKD patients.

• Authors: Antonio Bellasi, Andrea Galassi, Paolo Salvi, Mario Cozzolino
• Journal: Blood purification (Blood Purif) Vol. 36 Issue 1 Pg. 12-6 ( 2013) ISSN: 1421-9735 [Electronic] Switzerland
• PMID: 23736115 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 S. Karger AG, Basel.

Chemical References

• Bone Density Conservation Agents
• Ergocalciferols
• Vitamin D
• paricalcitol

Topics

• Bone Density Conservation Agents (therapeutic use)
• Bone Diseases, Metabolic (drug therapy, epidemiology, etiology)
• Cardiovascular Diseases (complications, metabolism, pathology)
• Ergocalciferols (therapeutic use)
• Humans
• Randomized Controlled Trials as Topic
• Renal Insufficiency, Chronic (complications, drug therapy)
• Treatment Outcome
• Vitamin D (metabolism)